Collaborating Authors

AI platform says Olumiant could be repurposed for Alzheimer's


With so many novel drug candidates for Alzheimer's disease failing in clinical development, researchers in the US have started using artificial intelligence (AI) to screen already-approved therapies for activity against the neurodegenerative disorder. A team based at Massachusetts General Hospital and Harvard Medical School has come up with an AI algorithm – called DRIAD (Drug Repurposing In Alzheimer's Disease) – that it hopes will not only find treatments but also tease out new therapeutic targets. The AI uses machine learning to measure what happens to human brain neural cells when treated with a drug, and could be "a more rapid and less expensive option" than clinical trials of novel therapeutics, according to the researchers. In the journal Nature Communications, Harvard informatics specialist Artem Sokolov and colleagues report that early studies with the platform based on 80 approved drugs suggest Eli Lilly's Olumiant (baricitinib) as a possible candidate for repurposing as an AD therapy. It's not the first time that AI has suggested a new role for Olumiant, which is approved as an arthritis drug.

Treating Alzheimer's as having many causes may help us beat it

New Scientist

FOR nearly three decades, we have waited anxiously for a blockbuster drug that could defeat Alzheimer's disease. We believed we had identified the culprit behind this debilitating condition: sticky clumps of the protein beta-amyloid in the brain. Even as drug after drug homing in on this target failed to make a difference to symptoms, we continued to pour more money into the effort. Regrettably, it is now becoming clear that this time could have been better spent zooming out from beta-amyloid, to look at the big picture of possible Alzheimer's causes.

Bill Gates Gives $50 Million to Combat Alzheimer's

U.S. News

Gates says the first treatments for the disease might not be feasible for a decade or more and would initially be expensive. He says the Gates Foundation might consider how to expand access in poorer countries when treatments are developed.

Eisai sees potential of new Alzheimer's drug but costs remain concern

The Japan Times

Eisai Co. CEO Haruo Naito said Wednesday that a new drug for Alzheimer's disease it has developed with U.S. firm Biogen Inc. has the potential to become a "blockbuster" product. The approval by the U.S. Food and Drug Administration on Monday of the drug Aduhelm raised hopes for the treatment of Alzheimer's disease. But concern remains about higher medical costs as a patient would be charged $56,000 a year. Speaking in an online news conference, Naito said the pricing of the drug should reflect multiple factors, such as the impact on the families of patients taking it. "We believe it has the potential to make a huge contribution as a blockbuster drug," he said, while adding that people on low incomes should also be able to receive the drug.

6 Effective Ways To Prevent Alzheimer's


Alzheimer's disease is on the rise and every 3 seconds, someone in the world seems to have been developing it. Since there is no cure yet to stop or slow down its progression, it can be wise to prevent it in the first place. Nowadays there are several genetic testing companies that can identify your risk for diseases like Alzheimer's. Here are a few ways that can help prevent Alzheimer's: Also, several autopsies have found that a majority of people with Alzheimer's disease also had cardiovascular diseases. It is assumed that plaques and tangles present in the brain can remain in the brain and not show any symptoms unless there is evidence of vascular diseases.